{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T00:19:15Z","timestamp":1793233155026,"version":"4.5.0"},"reference-count":109,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T00:00:00Z","timestamp":1737331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Med"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1038\/s41591-024-03412-w","type":"journal-article","created":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T11:02:03Z","timestamp":1737370923000},"page":"951-962","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":304,"title":["Mapping the effectiveness and risks of GLP-1 receptor agonists"],"prefix":"10.1038","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2457-9382","authenticated-orcid":false,"given":"Yan","family":"Xie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taeyoung","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2600-0434","authenticated-orcid":false,"given":"Ziyad","family":"Al-Aly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,20]]},"reference":[{"key":"3412_CR1","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","volume":"373","author":"MA Pfeffer","year":"2015","unstructured":"Pfeffer, M. A. et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N. Engl. J. Med. 373, 2247\u20132257 (2015).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375, 311\u2013322 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR3","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","volume":"375","author":"SP Marso","year":"2016","unstructured":"Marso, S. P. et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 375, 1834\u20131844 (2016).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR4","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","volume":"381","author":"M Husain","year":"2019","unstructured":"Husain, M. et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N. Engl. J. Med. 381, 841\u2013851 (2019).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR5","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","volume":"377","author":"RR Holman","year":"2017","unstructured":"Holman, R. R. et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 377, 1228\u20131239 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","volume":"392","author":"AF Hernandez","year":"2018","unstructured":"Hernandez, A. F. et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 392, 1519\u20131529 (2018).","journal-title":"Lancet"},{"key":"3412_CR7","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 394, 121\u2013130 (2019).","journal-title":"Lancet"},{"key":"3412_CR8","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","volume":"385","author":"HC Gerstein","year":"2021","unstructured":"Gerstein, H. C. et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N. Engl. J. Med. 385, 896\u2013907 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","volume":"391","author":"Perkovic, V. et al.","year":"2024","unstructured":"Perkovic, V. et al. Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N. Engl. J. Med. 391, 109\u2013121 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR10","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1056\/NEJMoa2306963","volume":"389","author":"MN Kosiborod","year":"2023","unstructured":"Kosiborod, M. N. et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N. Engl. J. Med. 389, 1069\u20131084 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(19)31150-X","volume":"394","author":"HC Gerstein","year":"2019","unstructured":"Gerstein, H. C. et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet 394, 131\u2013138 (2019).","journal-title":"Lancet"},{"key":"3412_CR12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","volume":"377","author":"JFE Mann","year":"2017","unstructured":"Mann, J. F. E. et al. Liraglutide and renal outcomes in type 2 diabetes. N. Engl. J. Med. 377, 839\u2013848 (2017).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR13","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/S2213-8587(18)30268-7","volume":"6","author":"MHA Muskiet","year":"2018","unstructured":"Muskiet, M. H. A. et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 6, 859\u2013869 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3412_CR14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","volume":"6","author":"KR Tuttle","year":"2018","unstructured":"Tuttle, K. R. et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 6, 605\u2013617 (2018).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3412_CR15","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding, J. P. H. et al. Once-weekly semaglutide in adults with overweight or obesity. N. Engl. J. Med. 384, 989\u20131002 (2021).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR16","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","volume":"387","author":"AM Jastreboff","year":"2022","unstructured":"Jastreboff, A. M. et al. Tirzepatide once weekly for the treatment of obesity. N. Engl. J. Med. 387, 205\u2013216 (2022).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR17","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","volume":"382","author":"AS Kelly","year":"2020","unstructured":"Kelly, A. S. et al. A randomized, controlled trial of liraglutide for adolescents with obesity. N. Engl. J. Med. 382, 2117\u20132128 (2020).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR18","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","volume":"389","author":"S Wharton","year":"2023","unstructured":"Wharton, S. et al. Daily oral GLP-1 receptor agonist orforglipron for adults with obesity. N. Engl. J. Med. 389, 877\u2013888 (2023).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR19","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.japh.2023.10.002","volume":"64","author":"JH Watanabe","year":"2024","unstructured":"Watanabe, J. H., Kwon, J., Nan, B. & Reikes, A. Trends in glucagon-like peptide 1 receptor agonist use, 2014 to 2022. J. Am. Pharm. Assoc. 64, 133\u2013138 (2024).","journal-title":"J. Am. Pharm. Assoc."},{"key":"3412_CR20","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1001\/jama.2024.18219","volume":"332","author":"TA Hegland","year":"2024","unstructured":"Hegland, T.A., Fang, Z. & Bucher, K. GLP-1 medication use for type 2 diabetes has soared.JAMA 332, 952\u2013953 (2024).","journal-title":"JAMA"},{"key":"3412_CR21","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","volume":"330","author":"M Sodhi","year":"2023","unstructured":"Sodhi, M., Rezaeianzadeh, R., Kezouh, A. & Etminan, M. Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. JAMA 330, 1795\u20131797 (2023).","journal-title":"JAMA"},{"key":"3412_CR22","doi-asserted-by":"publisher","unstructured":"Vidal, J., Flores, L., Jim\u00e9nez, A., Pan\u00e9, A. & de Hollanda, A. What is the evidence regarding the safety of new obesity pharmacotherapies. Int. J. Obes. https:\/\/doi.org\/10.1038\/s41366-024-01488-5 (2024).","DOI":"10.1038\/s41366-024-01488-5"},{"key":"3412_CR23","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/s41591-023-02672-2","volume":"30","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat. Med. 30, 168\u2013176 (2024).","journal-title":"Nat. Med."},{"key":"3412_CR24","doi-asserted-by":"crossref","first-page":"739","DOI":"10.3390\/ijms23020739","volume":"23","author":"LF Laurindo","year":"2022","unstructured":"Laurindo, L. F. et al. GLP-1a: going beyond traditional use. Int. J. Mol. Sci. 23, 739 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"3412_CR25","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1001\/jama.2024.1017","volume":"331","author":"R Rubin","year":"2024","unstructured":"Rubin, R. Could GLP-1 receptor agonists like semaglutide treat addiction, Alzheimer disease, and other conditions? JAMA 331, 1519\u20131521 (2024).","journal-title":"JAMA"},{"key":"3412_CR26","volume":"15","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real-world population. Nat. Commun. 15, 4548 (2024).","journal-title":"Nat. Commun."},{"key":"3412_CR27","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.7326\/M23-2718","volume":"177","author":"W Wang","year":"2024","unstructured":"Wang, W. et al. Association of semaglutide with tobacco use disorder in patients with type 2 diabetes: target trial emulation using real-world data. Ann. Intern. Med. 177, 1016\u20131027 (2024).","journal-title":"Ann. Intern. Med."},{"key":"3412_CR28","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1126\/science.adn4128","volume":"385","author":"DJ Drucker","year":"2024","unstructured":"Drucker, D. J. The benefits of GLP-1 drugs beyond obesity. Science 385, 258\u2013260 (2024).","journal-title":"Science"},{"key":"3412_CR29","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/d41586-024-03074-1","volume":"633","author":"M Lenharo","year":"2024","unstructured":"Lenharo, M. Why do obesity drugs seem to treat so many other ailments? Nature 633, 758\u2013760 (2024).","journal-title":"Nature"},{"key":"3412_CR30","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/s41586-021-03553-9","volume":"594","author":"Z Al-Aly","year":"2021","unstructured":"Al-Aly, Z., Xie, Y. & Bowe, B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 594, 259\u2013264 (2021).","journal-title":"Nature"},{"key":"3412_CR31","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1038\/s41591-023-02634-8","volume":"29","author":"L Leggio","year":"2023","unstructured":"Leggio, L. et al. GLP-1 receptor agonists are promising but unproven treatments for alcohol and substance use disorders. Nat. Med. 29, 2993\u20132995 (2023).","journal-title":"Nat. Med."},{"key":"3412_CR32","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1111\/bcpt.13776","volume":"131","author":"IK Wium-Andersen","year":"2022","unstructured":"Wium-Andersen, I. K. et al. Use of GLP-1 receptor agonists and subsequent risk of alcohol-related events. A nationwide register-based cohort and self-controlled case series study. Basic Clin. Pharmacol. Toxicol. 131, 372\u2013379 (2022).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"3412_CR33","doi-asserted-by":"crossref","first-page":"e159863","DOI":"10.1172\/jci.insight.159863","volume":"7","author":"MK Klausen","year":"2022","unstructured":"Klausen, M. K. et al. Exenatide once weekly for alcohol use disorder investigated in a randomized, placebo-controlled clinical trial. JCI Insight 7, e159863 (2022).","journal-title":"JCI Insight"},{"key":"3412_CR34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1097\/ADM.0000000000001147","volume":"17","author":"L Yammine","year":"2023","unstructured":"Yammine, L., Balderas, J. C., Weaver, M. F. & Schmitz, J. M. Feasibility of exenatide, a GLP-1R agonist, for treating cocaine use disorder: a case series study. J. Addict. Med. 17, 481\u2013484 (2023).","journal-title":"J. Addict. Med."},{"key":"3412_CR35","doi-asserted-by":"crossref","DOI":"10.1016\/j.drugalcdep.2021.108614","volume":"221","author":"GA Angarita","year":"2021","unstructured":"Angarita, G. A. et al. Testing the effects of the GLP-1 receptor agonist exenatide on cocaine self-administration and subjective responses in humans with cocaine use disorder. Drug Alcohol Depend. 221, 108614 (2021).","journal-title":"Drug Alcohol Depend."},{"key":"3412_CR36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.physbeh.2013.03.008","volume":"114\u2212115","author":"TS Dixit","year":"2013","unstructured":"Dixit, T. S., Sharma, A. N., Lucot, J. B. & Elased, K. M. Antipsychotic-like effect of GLP-1 agonist liraglutide but not DPP-IV inhibitor sitagliptin in mouse model for psychosis. Physiol. Behav. 114\u2212115, 38\u201341 (2013).","journal-title":"Physiol. Behav."},{"key":"3412_CR37","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1177\/02537176241246744","volume":"46","author":"S Gunturu","year":"2024","unstructured":"Gunturu, S. The potential role of GLP-1 agonists in psychiatric disorders: a paradigm shift in mental health treatment. Indian J. Psychol. Med. 46, 193\u2013195 (2024).","journal-title":"Indian J. Psychol. Med."},{"key":"3412_CR38","doi-asserted-by":"crossref","first-page":"A4","DOI":"10.1176\/appi.neuropsych.20240118","volume":"36","author":"W L\u00f3pez-Ojeda","year":"2024","unstructured":"L\u00f3pez-Ojeda, W. & Hurley, R. A. Glucagon-like peptide 1: an introduction and possible implications for neuropsychiatry. J. Neuropsychiatry Clin. Neurosci. 36, A4\u2013A86 (2024).","journal-title":"J. Neuropsychiatry Clin. Neurosci."},{"key":"3412_CR39","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/13543784.2021.1951702","volume":"30","author":"J Flintoff","year":"2021","unstructured":"Flintoff, J., Kesby, J. P., Siskind, D. & Burne, T. H. J. Treating cognitive impairment in schizophrenia with GLP-1RAs: an overview of their therapeutic potential. Expert Opin. Investig. Drugs 30, 877\u2013891 (2021).","journal-title":"Expert Opin. Investig. Drugs"},{"key":"3412_CR40","unstructured":"European Medicines Agency. Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8\u221211 April 2024. https:\/\/www.ema.europa.eu\/en\/news\/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024 (12 April 2024)."},{"key":"3412_CR41","doi-asserted-by":"crossref","first-page":"1033479","DOI":"10.3389\/fendo.2022.1033479","volume":"13","author":"H Du","year":"2022","unstructured":"Du, H., Meng, X., Yao, Y. & Xu, J. The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer\u2019s disease. Front. Endocrinol. 13, 1033479 (2022).","journal-title":"Front. Endocrinol."},{"key":"3412_CR42","first-page":"31","volume":"12","author":"S Mehan","year":"2022","unstructured":"Mehan, S. et al. Potential roles of glucagon-like peptide-1 and its analogues in dementia targeting impaired insulin secretion and neurodegeneration. Degener. Neurol. Neuromuscul. Dis. 12, 31\u201359 (2022).","journal-title":"Degener. Neurol. Neuromuscul. Dis."},{"key":"3412_CR43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.17925\/EE.2023.19.1.16","volume":"19","author":"IM Colin","year":"2023","unstructured":"Colin, I. M., Szczepanski, L. W., G\u00e9rard, A. C. & Elosegi, J. A. Emerging evidence for the use of antidiabetic drugs, glucagon-like peptide 1 receptor agonists, for the treatment of Alzheimer\u2019s disease. touchREV. Endocrinol. 19, 16\u201324 (2023).","journal-title":"touchREV. Endocrinol."},{"key":"3412_CR44","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/d41586-024-00118-4","volume":"626","author":"M Lenharo","year":"2024","unstructured":"Lenharo, M. Obesity drugs have another superpower: taming inflammation. Nature 626, 246 (2024).","journal-title":"Nature"},{"key":"3412_CR45","doi-asserted-by":"crossref","first-page":"e12268","DOI":"10.1002\/trc2.12268","volume":"8","author":"CH N\u00f8rgaard","year":"2022","unstructured":"N\u00f8rgaard, C. H. et al. Treatment with glucagon-like peptide-1 receptor agonists and incidence of dementia: data from pooled double-blind randomized controlled trials and nationwide disease and prescription registers. Alzheimer\u2019s Dement. 8, e12268 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"3412_CR46","doi-asserted-by":"crossref","first-page":"102726","DOI":"10.1016\/j.eclinm.2024.102726","volume":"74","author":"R De Giorgi","year":"2024","unstructured":"De Giorgi, R. et al. 12-month neurological and psychiatric outcomes of semaglutide use for type 2 diabetes: a propensity-score matched cohort study. eClinicalMedicine 74, 102726 (2024).","journal-title":"eClinicalMedicine"},{"key":"3412_CR47","doi-asserted-by":"crossref","DOI":"10.1002\/alz.062415","volume":"18","author":"A Atri","year":"2022","unstructured":"Atri, A. et al. evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating the neuroprotective effects of semaglutide in early Alzheimer\u2019s disease. Alzheimer\u2019s Dement. 18, e062415 (2022).","journal-title":"Alzheimer\u2019s Dement."},{"key":"3412_CR48","doi-asserted-by":"crossref","DOI":"10.1016\/j.npep.2022.102250","volume":"94","author":"MA Manavi","year":"2022","unstructured":"Manavi, M. A. Neuroprotective effects of glucagon-like peptide-1 (GLP-1) analogues in epilepsy and associated comorbidities. Neuropeptides 94, 102250 (2022).","journal-title":"Neuropeptides"},{"key":"3412_CR49","doi-asserted-by":"crossref","first-page":"219","DOI":"10.3892\/ijmm.2021.5052","volume":"48","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole\u2011kindled mice. Int. J. Mol. Med. 48, 219 (2021).","journal-title":"Int. J. Mol. Med."},{"key":"3412_CR50","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/brainsci9050108","volume":"9","author":"AM Hussein","year":"2019","unstructured":"Hussein, A. M. et al. Effects of GLP-1 receptor activation on a pentylenetetrazole\u2212kindling rat model. Brain Sci. 9, 108 (2019).","journal-title":"Brain Sci."},{"key":"3412_CR51","doi-asserted-by":"crossref","first-page":"136","DOI":"10.3389\/fphar.2020.00136","volume":"11","author":"S Liu","year":"2020","unstructured":"Liu, S. et al. The glucagon-like peptide-1 analogue liraglutide reduces seizures susceptibility, cognition dysfunction and neuronal apoptosis in a mouse model of Dravet syndrome. Front. Pharmacol. 11, 136 (2020).","journal-title":"Front. Pharmacol."},{"key":"3412_CR52","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","volume":"9","author":"N Sattar","year":"2021","unstructured":"Sattar, N. et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol. 9, 653\u2013662 (2021).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3412_CR53","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2337\/dbi16-0014","volume":"65","author":"G Jia","year":"2016","unstructured":"Jia, G., Aroor, A. R. & Sowers, J. R. Glucagon-like peptide 1 receptor activation and platelet function: beyond glycemic control. Diabetes 65, 1487\u20131489 (2016).","journal-title":"Diabetes"},{"key":"3412_CR54","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.cmet.2016.06.009","volume":"24","author":"DJ Drucker","year":"2016","unstructured":"Drucker, D. J. The cardiovascular biology of glucagon-like peptide-1. Cell Metab. 24, 15\u201330 (2016).","journal-title":"Cell Metab."},{"key":"3412_CR55","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1161\/ATVBAHA.119.313645","volume":"40","author":"M Sternkopf","year":"2020","unstructured":"Sternkopf, M. et al. Native, intact glucagon-like peptide 1 is a natural suppressor of thrombus growth under physiological flow conditions. Arter. Thromb. Vasc. Biol. 40, e65\u2013e77 (2020).","journal-title":"Arter. Thromb. Vasc. Biol."},{"key":"3412_CR56","doi-asserted-by":"crossref","first-page":"1620","DOI":"10.1111\/bph.13549","volume":"174","author":"S Steven","year":"2017","unstructured":"Steven, S. et al. Glucagon-like peptide-1 receptor signalling reduces microvascular thrombosis, nitro-oxidative stress and platelet activation in endotoxaemic mice. Br. J. Pharmacol. 174, 1620\u20131632 (2017).","journal-title":"Br. J. Pharmacol."},{"key":"3412_CR57","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.2337\/db15-1141","volume":"65","author":"A Cameron-Vendrig","year":"2016","unstructured":"Cameron-Vendrig, A. et al. Glucagon-like peptide 1 receptor activation attenuates platelet aggregation and thrombosis. Diabetes 65, 1714\u20131723 (2016).","journal-title":"Diabetes"},{"key":"3412_CR58","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.2147\/DDDT.S312347","volume":"15","author":"Y Zhang","year":"2021","unstructured":"Zhang, Y., Chen, R., Jia, Y., Chen, M. & Shuai, Z. Effects of exenatide on coagulation and platelet aggregation in patients with type 2 diabetes. Drug Des. Devel. Ther. 15, 3027\u20133040 (2021).","journal-title":"Drug Des. Devel. Ther."},{"key":"3412_CR59","doi-asserted-by":"crossref","first-page":"e0168878","DOI":"10.1371\/journal.pone.0168878","volume":"11","author":"LD Horvei","year":"2016","unstructured":"Horvei, L. D., Br\u00e6kkan, S. K. & Hansen, J. B. Weight change and risk of venous thromboembolism: the Troms\u00f8 study. PLoS ONE 11, e0168878 (2016).","journal-title":"PLoS ONE"},{"key":"3412_CR60","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1161\/HYPERTENSIONAHA.123.22022","volume":"81","author":"JA de Lemos","year":"2024","unstructured":"de Lemos, J. A. et al. Tirzepatide reduces 24-hour ambulatory blood pressure in adults with body mass index \u226527 kg\/m2: SURMOUNT-1 Ambulatory Blood Pressure Monitoring Substudy. Hypertension 81, e41\u2013e43 (2024).","journal-title":"Hypertension"},{"key":"3412_CR61","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/s11154-014-9290-z","volume":"15","author":"AG Goodwill","year":"2014","unstructured":"Goodwill, A. G. et al. Cardiovascular and hemodynamic effects of glucagon-like peptide-1. Rev. Endocr. Metab. Disord. 15, 209\u2013217 (2014).","journal-title":"Rev. Endocr. Metab. Disord."},{"key":"3412_CR62","doi-asserted-by":"crossref","first-page":"102355","DOI":"10.1016\/j.coph.2023.102355","volume":"69","author":"JC Ribeiro-Silva","year":"2023","unstructured":"Ribeiro-Silva, J. C., Tavares, C. A. M. & Girardi, A. C. C. The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: a mini-review of the potential mechanisms. Curr. Opin. Pharmacol. 69, 102355 (2023).","journal-title":"Curr. Opin. Pharmacol."},{"key":"3412_CR63","doi-asserted-by":"crossref","DOI":"10.1007\/s11906-015-0621-6","volume":"18","author":"A Goud","year":"2016","unstructured":"Goud, A., Zhong, J., Peters, M., Brook, R. D. & Rajagopalan, S. GLP-1 agonists and blood pressure: a review of the evidence. Curr. Hypertens. Rep. 18, 16 (2016).","journal-title":"Curr. Hypertens. Rep."},{"key":"3412_CR64","volume":"12","author":"F Yang","year":"2021","unstructured":"Yang, F. et al. GLP-1 receptor: a new target for sepsis. Front. Pharmacol. 12, 706908 (2021).","journal-title":"Front. Pharmacol."},{"key":"3412_CR65","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.3390\/antiox10081175","volume":"10","author":"J Helmst\u00e4dter","year":"2021","unstructured":"Helmst\u00e4dter, J. et al. GLP-1 analog liraglutide improves vascular function in polymicrobial sepsis by reduction of oxidative stress and inflammation. Antioxidants 10, 1175 (2021).","journal-title":"Antioxidants"},{"key":"3412_CR66","volume":"363","author":"H Yi","year":"2023","unstructured":"Yi, H. et al. Activation of glucagon-like peptide-1 receptor in microglia exerts protective effects against sepsis-induced encephalopathy via attenuating endoplasmic reticulum stress-associated inflammation and apoptosis in a mouse model of sepsis. Exp. Neurol. 363, 114348 (2023).","journal-title":"Exp. Neurol."},{"key":"3412_CR67","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1016\/j.jacc.2024.08.007","volume":"84","author":"B Scirica","year":"2024","unstructured":"Scirica, B. et al. The effect of semaglutide on mortality and COVID-19\u2013related deaths.JACC 84, 1632\u20131642 (2024).","journal-title":"JACC"},{"key":"3412_CR68","doi-asserted-by":"crossref","first-page":"e2421305","DOI":"10.1001\/jamanetworkopen.2024.21305","volume":"7","author":"L Wang","year":"2024","unstructured":"Wang, L., Xu, R., Kaelber, D. C. & Berger, N. A. Glucagon-like peptide 1 receptor agonists and 13 obesity-associated cancers in patients with type 2 diabetes. JAMA Netw. Open 7, e2421305 (2024).","journal-title":"JAMA Netw. Open"},{"key":"3412_CR69","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s13098-023-01118-6","volume":"15","author":"M Yu","year":"2023","unstructured":"Yu, M. et al. The relationship between the use of GLP-1 receptor agonists and the incidence of respiratory illness: a meta-analysis of randomized controlled trials. Diabetol. Metab. Syndr. 15, 164 (2023).","journal-title":"Diabetol. Metab. Syndr."},{"key":"3412_CR70","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2147\/COPD.S350133","volume":"17","author":"AD Altintas Dogan","year":"2022","unstructured":"Altintas Dogan, A. D. et al. Respiratory effects of treatment with a glucagon-like peptide-1 receptor agonist in patients suffering from obesity and chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 17, 405\u2013414 (2022).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"3412_CR71","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1164\/rccm.202303-0491OC","volume":"208","author":"D Foer","year":"2023","unstructured":"Foer, D. et al. Association of GLP-1 receptor agonists with chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes. Am. J. Respir. Crit. Care Med. 208, 1088\u20131100 (2023).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"3412_CR72","doi-asserted-by":"crossref","first-page":"e071380","DOI":"10.1136\/bmj-2022-071380","volume":"379","author":"R Pradhan","year":"2022","unstructured":"Pradhan, R. et al. Novel antihyperglycaemic drugs and prevention of chronic obstructive pulmonary disease exacerbations among patients with type 2 diabetes: population based cohort study. BMJ 379, e071380 (2022).","journal-title":"BMJ"},{"key":"3412_CR73","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1053\/j.gastro.2024.03.015","volume":"167","author":"YH Yeo","year":"2024","unstructured":"Yeo, Y.H. et al. Increased risk of aspiration pneumonia associated with endoscopic procedures among patients with glucagon-like peptide 1 receptor agonist use.Gastroenterology 167, 402\u2013404 (2024).","journal-title":"Gastroenterology"},{"key":"3412_CR74","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.2024.5003","volume":"331","author":"AA Dixit","year":"2024","unstructured":"Dixit, A. A., Bateman, B. T., Hawn, M. T., Odden, M. C. & Sun, E. C. Preoperative GLP-1 receptor agonist use and risk of postoperative respiratory complications. JAMA 331, 1672\u20131673 (2024).","journal-title":"JAMA"},{"key":"3412_CR75","doi-asserted-by":"crossref","first-page":"129","DOI":"10.2147\/COPD.S393323","volume":"18","author":"W Wang","year":"2023","unstructured":"Wang, W. et al. The role of glucagon-like peptide-1 receptor agonists in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 18, 129\u2013137 (2023).","journal-title":"Int. J. Chron. Obstruct. Pulmon. Dis."},{"key":"3412_CR76","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-023-02420-6","volume":"29","author":"C Langenberg","year":"2023","unstructured":"Langenberg, C., Hingorani, A. D. & Whitty, C. J. M. Biological and functional multimorbidity\u2014from mechanisms to management. Nat. Med. 29, 1649\u20131657 (2023).","journal-title":"Nat. Med."},{"key":"3412_CR77","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1056\/NEJMoa2403211","volume":"391","author":"Y Xie","year":"2024","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Postacute sequelae of SARS-CoV-2 infection in the pre-Delta, Delta, and Omicron eras. N. Engl. J. Med. 391, 515\u2013525 (2024).","journal-title":"N. Engl. J. Med."},{"key":"3412_CR78","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/s41591-024-02987-8","volume":"30","author":"M Cai","year":"2024","unstructured":"Cai, M., Xie, Y., Topol, E. J. & Al-Aly, Z. Three-year outcomes of post-acute sequelae of COVID-19. Nat. Med. 30, 1564\u20131573 (2024).","journal-title":"Nat. Med."},{"key":"3412_CR79","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1038\/s41591-023-02521-2","volume":"29","author":"B Bowe","year":"2023","unstructured":"Bowe, B., Xie, Y. & Al-Aly, Z. Postacute sequelae of COVID-19 at 2 years. Nat. Med. 29, 2347\u20132357 (2023).","journal-title":"Nat. Med."},{"key":"3412_CR80","volume":"14","author":"E Xu","year":"2023","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Long-term gastrointestinal outcomes of COVID-19. Nat. Commun. 14, 983 (2023).","journal-title":"Nat. Commun."},{"key":"3412_CR81","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/S2213-8587(22)00355-2","volume":"11","author":"E Xu","year":"2023","unstructured":"Xu, E., Xie, Y. & Al-Aly, Z. Risks and burdens of incident dyslipidaemia in long COVID: a cohort study. Lancet Diabetes Endocrinol. 11, 120\u2013128 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3412_CR82","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S1473-3099(23)00684-9","volume":"24","author":"Y Xie","year":"2024","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study. Lancet Infect. Dis. 24, 239\u2013255 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"3412_CR83","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1126\/science.adl0867","volume":"383","author":"Z Al-Aly","year":"2024","unstructured":"Al-Aly, Z. & Topol, E. Solving the puzzle of long Covid. Science 383, 830\u2013832 (2024).","journal-title":"Science"},{"key":"3412_CR84","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1038\/s41591-024-03173-6","volume":"30","author":"Z Al-Aly","year":"2024","unstructured":"Al-Aly, Z. et al. Long COVID science, research and policy. Nat. Med. 30, 2148\u20132164 (2024).","journal-title":"Nat. Med."},{"key":"3412_CR85","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.1681\/ASN.2015121377","volume":"27","author":"Y Xie","year":"2016","unstructured":"Xie, Y. et al. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J. Am. Soc. Nephrol. 27, 3153\u20133163 (2016).","journal-title":"J. Am. Soc. Nephrol."},{"key":"3412_CR86","doi-asserted-by":"crossref","first-page":"e015735","DOI":"10.1136\/bmjopen-2016-015735","volume":"7","author":"Y Xie","year":"2017","unstructured":"Xie, Y. et al. Risk of death among users of proton pump inhibitors: a longitudinal observational cohort study of United States veterans. BMJ Open 7, e015735 (2017).","journal-title":"BMJ Open"},{"key":"3412_CR87","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.kint.2016.12.021","volume":"91","author":"Y Xie","year":"2017","unstructured":"Xie, Y. et al. Long-term kidney outcomes among users of proton pump inhibitors without intervening acute kidney injury. Kidney Int. 91, 1482\u20131494 (2017).","journal-title":"Kidney Int."},{"key":"3412_CR88","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.kint.2017.08.033","volume":"93","author":"Y Xie","year":"2018","unstructured":"Xie, Y. et al. Higher blood urea nitrogen is associated with increased risk of incident diabetes mellitus. Kidney Int. 93, 741\u2013752 (2018).","journal-title":"Kidney Int."},{"key":"3412_CR89","unstructured":"Maynard, C. Ascertaining veterans\u2019 vital status: VA data sources for mortality ascertainment and cause of death. https:\/\/www.hsrd.research.va.gov\/for_researchers\/cyber_seminars\/archives\/3783-notes.pdf (2017)."},{"key":"3412_CR90","doi-asserted-by":"crossref","first-page":"e2033953","DOI":"10.1001\/jamanetworkopen.2020.33953","volume":"4","author":"M Cai","year":"2021","unstructured":"Cai, M. et al. Temporal trends in incidence rates of lower extremity amputation and associated risk factors among patients using Veterans Health Administration services from 2008 to 2018. JAMA Netw. Open 4, e2033953 (2021).","journal-title":"JAMA Netw. Open"},{"key":"3412_CR91","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/S2213-8587(23)00171-7","volume":"11","author":"Y Xie","year":"2023","unstructured":"Xie, Y. et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records. Lancet Diabetes Endocrinol. 11, 644\u2013656 (2023).","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3412_CR92","doi-asserted-by":"crossref","first-page":"e020237","DOI":"10.1161\/JAHA.120.020237","volume":"10","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Clinical implications of estimated glomerular filtration rate dip following sodium\u2212glucose cotransporter-2 inhibitor initiation on cardiovascular and kidney outcomes. J. Am. Heart Assoc. 10, e020237 (2021).","journal-title":"J. Am. Heart Assoc."},{"key":"3412_CR93","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1001\/jamainternmed.2021.2488","volume":"181","author":"Y Xie","year":"2021","unstructured":"Xie, Y. et al. Comparative effectiveness of sodium\u2212glucose cotransporter 2 inhibitors vs sulfonylureas in patients with type 2 diabetes. JAMA Intern. Med. 181, 1043\u20131053 (2021).","journal-title":"JAMA Intern. Med."},{"key":"3412_CR94","doi-asserted-by":"crossref","first-page":"2859","DOI":"10.2337\/dc20-1890","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. Comparative effectiveness of SGLT2 inhibitors, GLP-1 receptor agonists, DPP-4 inhibitors, and sulfonylureas on risk of kidney outcomes: emulation of a target trial using health care databases. Diabetes Care 43, 2859\u20132869 (2020).","journal-title":"Diabetes Care"},{"key":"3412_CR95","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.2337\/dc20-1231","volume":"43","author":"Y Xie","year":"2020","unstructured":"Xie, Y. et al. Comparative effectiveness of the sodium\u2212glucose cotransporter 2 inhibitor empagliflozin versus other antihyperglycemics on risk of major adverse kidney events. Diabetes Care 43, 2785\u20132795 (2020).","journal-title":"Diabetes Care"},{"key":"3412_CR96","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","volume":"183","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Nirmatrelvir and the risk of post-acute sequelae of COVID-19.JAMA Intern. Med. 183, 554\u2013564 (2023).","journal-title":"JAMA Intern. Med."},{"key":"3412_CR97","doi-asserted-by":"crossref","first-page":"e073312","DOI":"10.1136\/bmj-2022-073312","volume":"381","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Bowe, B. & Al-Aly, Z. Nirmatrelvir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records. BMJ 381, e073312 (2023).","journal-title":"BMJ"},{"key":"3412_CR98","doi-asserted-by":"crossref","first-page":"e072705","DOI":"10.1136\/bmj-2022-072705","volume":"380","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Bowe, B. & Al-Aly, Z. Molnupiravir and risk of hospital admission or death in adults with Covid-19: emulation of a randomized target trial using electronic health records. BMJ 380, e072705 (2023).","journal-title":"BMJ"},{"key":"3412_CR99","doi-asserted-by":"crossref","first-page":"e074572","DOI":"10.1136\/bmj-2022-074572","volume":"381","author":"Y Xie","year":"2023","unstructured":"Xie, Y., Choi, T. & Al-Aly, Z. Molnupiravir and risk of post-acute sequelae of Covid-19: cohort study. BMJ 381, e074572 (2023).","journal-title":"BMJ"},{"key":"3412_CR100","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/0962280206074463","volume":"16","author":"S van Buuren","year":"2007","unstructured":"van Buuren, S. Multiple imputation of discrete and continuous data by fully conditional specification. Stat. Methods Med. Res. 16, 219\u2013242 (2007).","journal-title":"Stat. Methods Med. Res."},{"key":"3412_CR101","doi-asserted-by":"crossref","unstructured":"Harrell, F. E. Regression Modeling Strategies: With Applications to Linear Models, Logistic and Ordinal Regression, and Survival Analysis (Springer, 2015).","DOI":"10.1007\/978-3-319-19425-7"},{"key":"3412_CR102","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2147\/CLEP.S166545","volume":"10","author":"S Schneeweiss","year":"2018","unstructured":"Schneeweiss, S. Automated data-adaptive analytics for electronic healthcare data to study causal treatment effects. Clin. Epidemiol. 10, 771\u2013788 (2018).","journal-title":"Clin. Epidemiol."},{"key":"3412_CR103","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1097\/EDE.0b013e3181a663cc","volume":"20","author":"S Schneeweiss","year":"2009","unstructured":"Schneeweiss, S. et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 20, 512\u2013522 (2009).","journal-title":"Epidemiology"},{"key":"3412_CR104","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity\u2010score matched samples. Stat. Med. 28, 3083\u20133107 (2009).","journal-title":"Stat. Med."},{"key":"3412_CR105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/biomet\/asn055","volume":"96","author":"RK Crump","year":"2009","unstructured":"Crump, R. K., Hotz, V. J., Imbens, G. W. & Mitnik, O. A. Dealing with limited overlap in estimation of average treatment effects. Biometrika 96, 187\u2013199 (2009).","journal-title":"Biometrika"},{"key":"3412_CR106","unstructured":"Hernan, M. A. & Robins, J. M. Causal Inference: What If (CRC Press, 2010)."},{"key":"3412_CR107","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1200\/JCO.2014.55.2208","volume":"32","author":"H Uno","year":"2014","unstructured":"Uno, H. et al. Moving beyond the hazard ratio in quantifying the between-group difference in survival analysis. J. Clin. Oncol. 32, 2380\u20132385 (2014).","journal-title":"J. Clin. Oncol."},{"key":"3412_CR108","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s10985-004-4771-0","volume":"10","author":"PK Andersen","year":"2004","unstructured":"Andersen, P. K., Hansen, M. G. & Klein, J. P. Regression analysis of restricted mean survival time based on pseudo-observations. Lifetime Data Anal. 10, 335\u2013350 (2004).","journal-title":"Lifetime Data Anal."},{"key":"3412_CR109","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. B 57, 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. B"}],"updated-by":[{"DOI":"10.1038\/s41591-025-03542-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,1,31]],"date-time":"2025-01-31T00:00:00Z","timestamp":1738281600000}}],"container-title":["Nature Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03412-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03412-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03412-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T08:27:09Z","timestamp":1742372829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41591-024-03412-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,20]]},"references-count":109,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["3412"],"URL":"https:\/\/doi.org\/10.1038\/s41591-024-03412-w","relation":{},"ISSN":["1078-8956","1546-170X"],"issn-type":[{"value":"1078-8956","type":"print"},{"value":"1546-170X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,20]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41591-025-03542-9","URL":"https:\/\/doi.org\/10.1038\/s41591-025-03542-9","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Y.X. and Z.A.A. are uncompensated consultants for Pfizer. No other potential competing interests relevant to this article are reported.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}